Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: A report of three cases

Transplant Infectious Disease

Volumn 17, Issue 1, 2015, Pages 147-153

  Righi, E ^a   Londero, A ^a   Pea, F ^a   Bonora, S ^b   Nasta, P ^c   Della Siega, P ^a   Delle Foglie, P ^d   Villa, G ^a   Giglio, O ^e   Dal Zoppo, S ^c   Baccarani, U ^a   Bassetti, M ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d Trento Hospital   (Italy)

^e SANT ANNA HOSPITAL   (Italy)

Author keywords

Antiretrovirals; C ART; Cirrhosis; HIV HCV coinfection; Liver transplant; Therapaeutic drug monitoring

Indexed keywords

ATAZANAVIR; BILIRUBIN; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; DARUNAVIR PLUS RITONAVIR; DIURETIC AGENT; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INSULIN; INTERFERON; LAMIVUDINE; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; TACROLIMUS; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTIRETROVIRUS AGENT; CYCLOHEXANE DERIVATIVE; DARUNAVIR; PYRIDAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BILIARY STENT; CASE REPORT; CHOLESTASIS; CLINICAL FEATURE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTRAHEPATIC BILE DUCT OBSTRUCTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERBILIRUBINEMIA; IMMUNOTHERAPY; INSULIN TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT; LIVER GRAFT REJECTION; MALE; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; MIXED INFECTION; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARACENTESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; VIRUS REACTIVATION; ADVERSE EFFECTS; BLOOD; COMPLICATION; DRUG MONITORING; HIV INFECTIONS; LIVER TRANSPLANTATION;

ANTI-RETROVIRAL AGENTS; COINFECTION; CYCLOHEXANES; DARUNAVIR; DRUG MONITORING; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PYRIDAZINES; TRIAZOLES;

EID: 84923222132     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12339     Document Type: Article

References (36)

1. Pelletier SJ, Norman SP, Christensen LL, Stock PG, Port FK, Merion RM. Review of transplantation in HIV patients during the HAART era. Clin Transpl 2004: 63-82.
2. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363 (21): 2004-2014.
3. Grossi PA, Righi E, Gasperina DD, et al. Report of four simultaneous pancreas-kidney transplants in HIV-positive recipients with favorable outcomes. Am J Transplant 2012; 12 (4): 1039-1045.
4. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18 (6): 716-726.
5. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42 (6): 799-805.
6. Baccarani U, Righi E, Adani GL, et al. Pros and cons of liver transplantation in human immunodeficiency virus infected recipients. World J Gastroenterol 2014; 20 (18): 5353-5362.
7. Moreno A, Cervera C, Fortun J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl 2012; 18 (1): 70-81.
8. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47 (2): 407-417.
9. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8 (2): 355-365.
10. van Maarseveen EM, Rogers CC, Trofe-Clark J, van Zuilen AD, Mudrikova T. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STD 2012; 26 (10): 568-581.
11. Frassetto L, Floren L, Barin B, et al. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos 2013; 34 (8): 442-451.
12. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4 (2): 481-508.
13. Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl 2009; 15 (Suppl 2): S70-S74.
14. McCabe SM, Ma Q, Slish JC, et al. Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment. Clin Pharmacokinet 2008; 47 (3): 153-172.
15. Berns JS, Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 2006; 1 (1): 117-129.
16. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40 (1): 174-181.
17. Barreiro P, Rodriguez-Novoa S, Labarga P, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 2007; 195 (7): 973-979.
18. Grossi PA. Update in HIV infection in organ transplantation. Curr Opin Organ Transplant 2012; 17 (6): 586-593.
19. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda, MD: Department of Health and Human Services (DHHS), 2011.
20. Everhart JE, Wright EC, Goodman ZD, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2010; 51 (2): 585-594.
21. D'Avolio A, Baietto L, Siccardi M, et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30 (6): 662-669.
22. Simiele M, Baietto L, Audino A, et al. A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma. J Pharm Biomed Anal 2014; 94C: 65-70.
23. Food and Drug Administration (FDA). Prezista (package insert), 2010. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021976s016lbl.pdf.
24. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Imm Def Syndr 2006; 43 (5): 509-515.
25. Kakuda TN, Wade JR, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther 2010; 88 (5): 695-703.
26. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46 (11): 941-952.
27. Tseng A, Nguyen ME, Cardella C, Humar A, Conly J. Probable interaction between efavirenz and cyclosporine. AIDS 2002; 16 (3): 505-506.
28. Tommasi C, Nicastri E, Gallo AL, et al. Raltegravir and darunavir plasma pharmacokinetic in HIV-1 infected patients with advanced liver disease. 11th International Workshop on Clinical Pharmacology and HIV Therapy. April 7-9, 2010. Sorrento, Italy. Abstract 10.
29. Hernandez-Novoa B, Moreno A, Perez-Elias MJ, et al. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C). J Antimicrob Chemother 2014; 69 (2): 471-475.
30. Cattaneo D, Gervasoni C, Meraviglia P, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother 2012; 67 (2): 460-464.
31. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9 (8): 1946-1952.
32. Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009; 48 (4): 489-492.
33. Barau C, Braun J, Vincent C, et al. Pharmacokinetic study of raltegravir in HIV-infected patients with end stage liver disease: LIVERAL ANRS 148 study. Poster 167, 20th Conference on Retroviruses and Opportunistic Infections (CROI) March 3-6, 2013, Atlanta, GA.
34. Dufty NE, Gilleran G, Hawkins D, Else LJ, Taylor S. Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma. J Antimicrob Chemother 2013; 68 (4): 972-974.
35. Pfizer, Inc. Selzentry [Prescribing Information]. New York: Pfizer, Inc., 2010.
36. Pau AK, Penzak SR, Boyd SD, McLaughlin M, Morse CG. Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma. Pharmacotherapy 2012; 32 (1): e1-e6.